Professor Sjöström’s reply

  • L. Sjöström


Obesity Obese Patient Coronary Heart Disease Risk Orlistat Great Weight Loss 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Lindgarde F.: The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: the Swedish Multimorbidity Study. J. Intern. Med., 248, 245–254, 2000.PubMedCrossRefGoogle Scholar
  2. 2.
    Finer N., James W.P., Kopelman P.G., Lean M.E., Williams G.: One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor. Int. J. Obes., 24, 306–313, 2000.CrossRefGoogle Scholar
  3. 3.
    Rossner S., Sjöström L., Noack R., Meinders A.E., Noseda G.: Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. Obes. Res., 8, 49–61, 2000.PubMedCrossRefGoogle Scholar
  4. 4.
    Hauptman J., Lucas C., Boldrin M.N., Collins H., Segal K.R.: Orlistat in the long-term treatment of obesity in primary care settings. Arch. Fam. Med., 9, 160–167, 2000.PubMedCrossRefGoogle Scholar
  5. 5.
    Micic D., Ivkovic-Lazar T., Dragojevic R., Jorga J., Stokic E., Hajdukovic Z.: Orlistat, a gastrointestinal lipase inhibitor, in therapy of obesity with concomitant hyperlipidemia. Med. Pregl., 52, 323–333, 1999.PubMedGoogle Scholar
  6. 6.
    Hill J.O., Hauptman J., Anderson J.W., Fujioka K., O’Neil P.M., Smith D.K., Zavoral J.H., Aronne L.J.: Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study. Am. J. Clin. Nutr., 69, 1108–1116, 1999.PubMedGoogle Scholar
  7. 7.
    Hollander P.A., Elbein S.C., Hirsch I.B., Kelley D., McGill J., Taylor T., Weiss S.R., Crockett S.E., Kaplan R.A., Comstock J., Lucas C.P., Lodewick P.A., Canovatchel W., Chung J., Hauptman J.: Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study. Diabetes Care, 21, 1288–1294, 1998.PubMedCrossRefGoogle Scholar
  8. 8.
    Van Gaal L.F., Broom J.I., Enzi G., Toplak H.: Efficacy and tolerability of orlistat in the treatment of obesity: a 6-month dose-ranging study. Orlistat Dose-Ranging Study Group. Eur. J. Clin. Pharmacol., 54, 125–132, 1998.PubMedCrossRefGoogle Scholar

Copyright information

© Editrice Kurtis 2001

Authors and Affiliations

  • L. Sjöström
    • 1
  1. 1.Sahlgrenska University HospitalGöteborgSweden

Personalised recommendations